Table S3: Major exposures prior to infection, France, September 2011-October 2012.

		All cases	A-cases	nonA-cases	P value
		(n=30)	(n=19)	(n=11)	
Hospitalisation room					
Protected ^a		18/23 (78%)	12/17 (71%)	6/6 (100%)	0.27
Standard		5/23 (22%)	5/17 (29%)	0/6 (0%)	0.27
Major exposures before	infection				
Medical treatments prior	or to infection (Pre-exposure)				
Posaconaz	ole	12/24 (50%)	9/17 (53%)	3/7 (42%)	
Daunorubi	cine	7/23 (30%)	5/17 (29%)	2/6 (33%)	1
Gentamici	ne (digestive tract decontamination)	14/23 (61%)	11/17 (65%)	3/7 (43%)	0.39
Colistine (digestive tract decontamination)	10/23 (43%)	7/17 (41%)	3/7 (43%)	1
Feeding					
Oral feeding	ng (protected ^b)	13/23 (56%)	9/17 (53%)	4/6 (66%)	0.67
Oral feeding	ng (normal)	7/23 (30%)	5/17 (30%)	2/6 (33%)	1
Oral feeding	ng (exclusive or associated with parenteral and/or enteral)	20/23 (87%)	14/17 (82%)	6/6 (100%)	0.53
Parenteral	nutrition ^c	16/23 (70%)	13/17 (76%)	3/6 (50%)	0.3
Food intake prior to infe	ection				
Dairy prod	lucts	15/18 (83%)	11/14 (79%)	4/4 (100%)	1
Yogourts ^c		13/18 (72%)	9/14 (71%)	4/4 (100%)	0.28
Cheese ^b		12/18 (67%)	8/14 (57%)	3/4 (75%)	1
Milk ^c		7/18 (39%)	3/14 (21%)	4/4 (100%)	0.01

^a including air filtred room with strict hygiene rules

^b raw foods or food at risk prohibited

^c analysis taking into account brands or producers gave only low exposition rates